Cargando…

Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma

BACKGROUND/OBJECTIVE: Although retinoid-associated central hypothyroidism has been reported on several occasions, there are very few studies on retinoid-associated central adrenal insufficiency. Here, we present the case of a patient with alitretinoin-induced central hypothyroidism and adrenal insuf...

Descripción completa

Detalles Bibliográficos
Autores principales: Marino, Amanda, Albanese, Isabella, Larose, Stephanie, Fantus, I. George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701901/
https://www.ncbi.nlm.nih.gov/pubmed/36447824
http://dx.doi.org/10.1016/j.aace.2022.08.004
_version_ 1784839644920152064
author Marino, Amanda
Albanese, Isabella
Larose, Stephanie
Fantus, I. George
author_facet Marino, Amanda
Albanese, Isabella
Larose, Stephanie
Fantus, I. George
author_sort Marino, Amanda
collection PubMed
description BACKGROUND/OBJECTIVE: Although retinoid-associated central hypothyroidism has been reported on several occasions, there are very few studies on retinoid-associated central adrenal insufficiency. Here, we present the case of a patient with alitretinoin-induced central hypothyroidism and adrenal insufficiency. CASE REPORT: An 86-year-old man with a diagnosis of cutaneous T-cell lymphoma, treated with oral alitretinoin 30 mg po daily, topical steroids, and ultraviolet light therapy presented to the emergency department with generalized weakness, decreased energy, orthostasis, and unexplained falls. Thyroid-stimulating hormone (TSH) was 0.31 mIU/L (normal range: 0.4-4.4) from 1.93 before alitretinoin therapy, whereas free thyroxine was 5.7 pmol/L (normal range: 8-18) and the AM cortisol was 40 nmol/L (normal range: 120-535); these values were suggestive of central hypothyroidism and adrenal insufficiency. Adrenocorticotropic hormone (ACTH) was not measured because of a laboratory error. Alitretinoin was stopped, and one dose of hydrocortisone 100mg IV was initiated, followed by maintenance doses of oral hydrocortisone 20mg qam and 10mg qpm. Levothyroxine (50μg ) daily was started 24 hours later. After stopping hydrocortisone for 24 hours, the AM cortisol and ACTH levels were 406 nmol/L and 2.18 pmol/L (normal range:1.6-13.9), respectively. He was discharged on thyroid hormone replacement therapy and glucocorticoids. Repeat thyroid function tests 6 weeks later showed a TSH of 0.4 mIU/L, and free thyroxine of 9.7 pmol/L. DISCUSSION: Alitretinoin activates nuclear receptors called retinoic acid receptors and retinoid X-receptors. Retinoic acid receptors and retinoid X-receptors are widely expressed in the anterior pituitary gland. RXR-selective ligands such as retinoids can suppress TSH secretion, resulting in central hypothyroidism. Retinoids have also been shown to decrease ACTH secretion, which can result in central adrenal insufficiency. CONCLUSION: Although central adrenal insufficiency and hypothyroidism have not been commonly reported in patients taking retinoids, they should always be considered when caring for these patients.
format Online
Article
Text
id pubmed-9701901
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Clinical Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-97019012022-11-28 Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma Marino, Amanda Albanese, Isabella Larose, Stephanie Fantus, I. George AACE Clin Case Rep Case Report BACKGROUND/OBJECTIVE: Although retinoid-associated central hypothyroidism has been reported on several occasions, there are very few studies on retinoid-associated central adrenal insufficiency. Here, we present the case of a patient with alitretinoin-induced central hypothyroidism and adrenal insufficiency. CASE REPORT: An 86-year-old man with a diagnosis of cutaneous T-cell lymphoma, treated with oral alitretinoin 30 mg po daily, topical steroids, and ultraviolet light therapy presented to the emergency department with generalized weakness, decreased energy, orthostasis, and unexplained falls. Thyroid-stimulating hormone (TSH) was 0.31 mIU/L (normal range: 0.4-4.4) from 1.93 before alitretinoin therapy, whereas free thyroxine was 5.7 pmol/L (normal range: 8-18) and the AM cortisol was 40 nmol/L (normal range: 120-535); these values were suggestive of central hypothyroidism and adrenal insufficiency. Adrenocorticotropic hormone (ACTH) was not measured because of a laboratory error. Alitretinoin was stopped, and one dose of hydrocortisone 100mg IV was initiated, followed by maintenance doses of oral hydrocortisone 20mg qam and 10mg qpm. Levothyroxine (50μg ) daily was started 24 hours later. After stopping hydrocortisone for 24 hours, the AM cortisol and ACTH levels were 406 nmol/L and 2.18 pmol/L (normal range:1.6-13.9), respectively. He was discharged on thyroid hormone replacement therapy and glucocorticoids. Repeat thyroid function tests 6 weeks later showed a TSH of 0.4 mIU/L, and free thyroxine of 9.7 pmol/L. DISCUSSION: Alitretinoin activates nuclear receptors called retinoic acid receptors and retinoid X-receptors. Retinoic acid receptors and retinoid X-receptors are widely expressed in the anterior pituitary gland. RXR-selective ligands such as retinoids can suppress TSH secretion, resulting in central hypothyroidism. Retinoids have also been shown to decrease ACTH secretion, which can result in central adrenal insufficiency. CONCLUSION: Although central adrenal insufficiency and hypothyroidism have not been commonly reported in patients taking retinoids, they should always be considered when caring for these patients. American Association of Clinical Endocrinology 2022-08-23 /pmc/articles/PMC9701901/ /pubmed/36447824 http://dx.doi.org/10.1016/j.aace.2022.08.004 Text en © 2022 Published by Elsevier Inc. on behalf of the AACE. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Marino, Amanda
Albanese, Isabella
Larose, Stephanie
Fantus, I. George
Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title_full Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title_fullStr Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title_full_unstemmed Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title_short Combined Central Hypothyroidism and Adrenal Insufficiency Associated with Retinoic Acid Therapy for Cutaneous T-Cell Lymphoma
title_sort combined central hypothyroidism and adrenal insufficiency associated with retinoic acid therapy for cutaneous t-cell lymphoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701901/
https://www.ncbi.nlm.nih.gov/pubmed/36447824
http://dx.doi.org/10.1016/j.aace.2022.08.004
work_keys_str_mv AT marinoamanda combinedcentralhypothyroidismandadrenalinsufficiencyassociatedwithretinoicacidtherapyforcutaneoustcelllymphoma
AT albaneseisabella combinedcentralhypothyroidismandadrenalinsufficiencyassociatedwithretinoicacidtherapyforcutaneoustcelllymphoma
AT larosestephanie combinedcentralhypothyroidismandadrenalinsufficiencyassociatedwithretinoicacidtherapyforcutaneoustcelllymphoma
AT fantusigeorge combinedcentralhypothyroidismandadrenalinsufficiencyassociatedwithretinoicacidtherapyforcutaneoustcelllymphoma